Conatus Pharmaceuticals Inc.

Available to platforms
R StocksTrader
Conatus Pharmaceuticals Inc. (Ticker: CNAT) was a biotechnology company focused on developing treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and liver fibrosis. Its lead product candidate, emricasan, aimed to reduce liver inflammation and improve liver function. In 2020, Conatus merged with Histogen Inc., transitioning its resources and focus to regenerative medicine and aesthetic dermatology.

Conatus Pharmaceuticals Inc. - CNAT stocks live chart

Analyze price movements of Conatus Pharmaceuticals Inc. online with R StocksTrader stock charts. You don't need to refresh chart as the quotes are updated automatically. View the current and previous CNAT quotes, get all necessary information for adding Conatus Pharmaceuticals Inc. to your investment portfolio.

You can invest in Conatus Pharmaceuticals Inc. and real stocks and CFDs on stocks of other American and European companies in R StocksTrader. Stocks, Indices, Metals: 12,000 assets in total are available for trading in the web terminal. Explore price movements of popular assets, like Conatus Pharmaceuticals Inc., in our "Charts" section and expand your trading opportunities by investing in new instruments.

Risk Warning: past performance of CNAT does not predict future returns.

FAQ

Open a trading account at RoboForex, decide on the number of assets to buy and then place an order for Conatus Pharmaceuticals Inc. (CNAT).

You can trade Conatus Pharmaceuticals Inc. (CNAT) on the R StocksTrader platform.

You can trade online Conatus Pharmaceuticals Inc. (CNAT) on Prime, ECN, Pro, or R StocksTrader accounts.